AKEEGA

Akeega is a medication used to treat castration-resistant prostate cancer in adult patients that has metastasized. It is prescribed when other methods of lowering testosterone levels have been ineffective.

Akeega may cause several side effects, with anaemia, high blood pressure, constipation, tiredness, nausea, thrombocytopenia, difficulty breathing, back pain, reduced appetite, and neutropenia being the most common ones. These side effects may affect more than 1 in 10 people.

The combination of niraparib and abiraterone acetate provides a two-pronged approach to effectively target tumors in patients with BRCA1/2 mutations in metastatic castration-resistant prostate cancer (mCRPC). Niraparib is an orally administered PARP inhibitor that specifically targets PARP-1 and PARP-2, demonstrating strong efficacy.

The suggested amount of AKEEGA is 200 mg of niraparib and 1,000 mg of abiraterone acetate taken orally once a day, along with 10 mg of prednisone daily. This combination should be continued until there is disease progression or if there are any adverse effects that are deemed unacceptable.

LOXAPINE (LOX a peen) is a medication used to treat schizophrenia. Its mechanism of action involves regulating the levels of dopamine and serotonin in the brain, which are important for mood, behaviors, and thoughts. LOXAPINE belongs to a class of drugs known as antipsychotics.

AKEEGA, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, has received approval from the US Food and Drug Administration (FDA) for its use in the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients.

Loxapine is a conventional antipsychotic medication used to alleviate the symptoms of schizophrenia, a mental disorder characterized by disturbed thinking, loss of interest, and intense or inappropriate emotions. Its mechanism of action involves reducing abnormal brain activity and excitement.

AKEEGA® is the initial and sole FDA-approved tablet that combines PARP inhibition and innovative hormonal therapy to offer precision medicine for patients diagnosed with BRCA+ mCRPC. AKEEGA® is prescribed alongside a daily dosage of 10 mg prednisone.

The suggested amount of AKEEGA is 200 mg of niraparib and 1,000 mg of abiraterone acetate taken orally once a day, along with 10 mg of prednisone daily. This combination should be continued until there is disease progression or if there are any adverse effects that are deemed unacceptable.

CSL Behring’s hemophilia B gene therapy Hemgenix, which costs $3.5 million per dose, was approved by the Food and Drug Administration in late 2020, making it the most expensive drug in the world.

Colchicine, also known as Colcrys or Mitigare, is a medication prescribed for the treatment and prevention of gout, a form of arthritis that causes severe pain. Nitroglycerin, morphine, phenazopyridine, phenobarbital, potassium chloride, and sodium fluoride are other medications that may be used for various medical purposes.

There are two groups of drugs. The first group consists of seven FDA-approved EGFR-TKIs, namely afatinib, brigatinib, dacomitinib, neratinib, osimertinib, pyrotinib, and vandetanib. The second group includes four drugs approved for cancer treatment outside of the USA.

In February 2022, Pacritinib was granted its initial approval in the United States. This approval allows for the treatment of adults who have intermediate- or high-risk primary or secondary myelofibrosis (specifically post-polycythemia vera or post-essential thrombocythemia) and have a platelet count below 50 × 109/L.

Amylyx’s ALS therapy, AMX0035, has received FDA approval for the treatment of amyotrophic lateral sclerosis (ALS). Despite the underwhelming data, the FDA has shown regulatory flexibility and granted full approval for this severe neurological disorder that leads to paralysis and death.

Nubeqa is prescribed for nonmetastatic castration-resistant prostate cancer (nmCRPC), but there are alternative medications that may be more suitable for your condition.

The FDA grants approval for new drugs and biological products for human use. This requires companies to provide evidence of the safety and effectiveness of their product for its intended purpose, as well as demonstrate their ability to manufacture the product according to federal quality standards.

The EMFACE Treatment is an FDA-cleared procedure that is completely pain-free and does not require any downtime. With EMFACE, you can experience a 37% reduction in wrinkles and a 23% increase in lift, all without the need for needles. This innovative mask targets multiple areas, including the forehead, eyebrows, cheeks, and jawline, treating elastin, collagen muscle, and connective tissue simultaneously. The results are truly dramatic.

pharma& GmbH now owns Rubraca® (rucaparib) tablets and acknowledges the significance of initiating and maintaining treatment with Rubraca for your eligible patients.

Enzalutamide (Xtandi, Astellas Pharma US, Inc.) was granted approval by the Food and Drug Administration on November 16, 2023, for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) in patients with high-risk biochemical recurrence at risk for metastasis (high-risk BCR).

Researchers discovered in 2023 that utilizing magnetic resonance imaging (MRI) to guide stereotactic body radiotherapy resulted in a notable decrease in moderate side effects and an enhancement in the quality of life for patients with prostate cancer, in comparison to radiotherapy guided by the standard of care.

After a median follow-up period of 15.9 months, it was found that patients who received Pluvicto treatment had a median progression-free survival of 12.02 months. On the other hand, patients who received a different ARPI treatment had a median progression-free survival of 5.59 months.

Radiation therapy is an excellent option for numerous men diagnosed with early-stage prostate cancer. It particularly stands out as the most suitable treatment for older individuals or those with underlying health conditions. External beam radiation is one of the various types of radiation therapy available.

The study, which has not yet been published, presented its results at the 2023 American Society of Oncology Annual Meeting in June. After approximately 17 months of follow-up, the combination of enzalutamide and talazoparib showed a 55% reduction in the risk of death or visible signs of tumor progression.

The 5-year survival rate for Stage-4 Prostate Cancer (IV) is 29%.

The price of a 1000 MBq/mL Pluvicto intravenous solution is approximately $45,657 for a single supply, with variations depending on the pharmacy.